Hengrui Medicine Carrelizumab: First PD-1 approved for first-line nasopharyngeal carcinoma indication

Progression-free survival

Nasopharyngeal carcinoma is one of the most common tumors in China, and 50% of nasopharyngeal carcinomas in the world occur in China

The approval of carrelizumab for nasopharyngeal carcinoma is based on the CAPTAIN-1ST study led by Professor Zhang Li from the Cancer Center of Sun Yat-sen University

A total of 263 subjects were enrolled in this study, all patients with late recurrence or metastasis, all with distant metastasis, were randomly enrolled according to 1:1, and the enrolled subjects received carrelizumab.

Carrelizumab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma is expected to become the new standard treatment for locally advanced recurrent/metastatic advanced nasopharyngeal carcinoma, which will enable more advanced noses Patients with pharyngeal cancer benefit

Carrelizumab

Shine at the ASCO annual meeting

Prior to this, Carrelizumab had been approved by the NMPA in May 2019 for the treatment of patients with relapsed or refractory classic Hodgkin’s lymphoma who had undergone at least second-line chemotherapy; received NMPA in March 2020 Approved for the treatment of patients with advanced hepatocellular carcinoma who have received sorafenib therapy and/or oxaliplatin-containing system chemotherapy; in June 2020, it was approved by the NMPA in combination with pemetrexed and carboplatin for the treatment of epidermal growth factor First-line treatment for non-squamous non-small cell lung cancer (NSCLC) that is negative for EGFR gene mutations and anaplastic lymphoma kinase (ALK) negative, and is not resectable; received NMPA approval in June 2020 Treatment of locally advanced or metastatic esophageal squamous cell carcinoma patients with disease progression or intolerance after previous first-line chemotherapy; NMPA approved in April 2021 for disease progression or intolerance after previous second-line chemotherapy or above Treatment of patients with advanced nasopharyngeal carcinoma

Since the advent of carrelizumab, clinical research results have been on the stage of international academic conferences for many times, and clinical research in the fields of nasopharyngeal cancer, liver cancer, esophageal cancer, lung cancer and other fields have successively topped the Lancet series of journals.

Benefit people's livelihood:

4 large adaptation syndrome has access to health insurance

For immunotherapeutic drugs, in addition to expanding indications and overcoming technical difficulties, lowering prices for medical insurance on the basis of excellent curative effects will also help make innovative drugs better benefit the people's livelihood

  As the leader of national medicine innovation, Hengrui Medicine has been adhering to the original research for many years, and is committed to providing good "weapons" for Chinese doctors and providing more treatment opportunities for Chinese patients

  The subsequent development of Karelizumab not only focuses on the combination of existing indications and cancer types, but also focuses on the expansion of indications for other cancer types